A downtrend has been apparent in Keros Therapeutics, Inc. (KROS) lately with too much selling pressure. The stock has declined 36.2% over the past four weeks. However, given the fact that it is now in ...

Keros Therapeutics, Inc. (KROS) shares soared 5.1% in the last trading session to close at $11.41. The move was backed by solid volume with far more shares changing hands than in a normal session.

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc.

Keros Therapeutics, Inc. (KROS) has been on a downward spiral lately with significant selling pressure. After declining 39.2% over the past four weeks, the stock looks well positioned for a trend ...

Kairos Pharma (NYSE American: KAPA) presented preclinical data on its GITR agonist, KROS 101, during the plenary session of the AACR-JCA conference.

Check the time stamp on this data. Updated AI-Generated Signals for Keros Therapeutics Inc. (KROS) available here: KROS. Type ...

A live audio webcast of the fireside chat presentation will be available at https://wsw.com/webcast/guggen2/kros/2033361 and an archived replay will be accessible in the Investors section of the Keros ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Exchange Traded Concepts LLC acquired a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and ...

Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So should Keros Therapeutics (NASDAQ:KROS) shareholders be worried about its cash burn?

In December, KROS Radio in Clinton, Iowa, was contacted by Tuomo Vesala, a 59-year-old carpenter, who heard the station's broadcast all the way from Finland — more than 4,000 miles away.